Metfonorm

Quick links to important sections

Metfonorm

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metfonorm

What is Metfonorm?

Metfonorm is an oral medication primarily used to manage blood glucose levels in individuals with type 2 diabetes. It belongs to a class of drugs known as biguanides, which work by improving the body's response to insulin and decreasing the amount of sugar produced and absorbed by the body.

Mechanism of Action

Metfonorm helps control blood sugar in three primary ways:

  • Reducing Glucose Production: It limits the amount of glucose (sugar) that the liver releases into the bloodstream.
  • Improving Insulin Sensitivity: It increases the sensitivity of muscle cells to insulin, allowing the body to use existing insulin more effectively to remove glucose from the blood.
  • Slowing Glucose Absorption: It delays the absorption of sugar from the intestines during the digestion process.

Therapeutic Use

In type 2 diabetes, the body either does not produce enough insulin or cannot use it normally, leading to high blood sugar levels. Metfonorm is used to help bring these levels into a target range. Unlike some other diabetes medications, biguanides like Metfonorm typically do not cause the body to produce more insulin, which reduces the likelihood of blood sugar dropping too low when the medication is used as a standalone treatment.

Effective management of blood sugar is a central component of long-term care for type 2 diabetes, often used in conjunction with specific dietary patterns and physical activity to support overall metabolic health.

Regulatory References

  1. Metformin - StatPearls - NCBI Bookshelf
  2. FDA Label (DailyMed)

What side effects are possible with Metfonorm?

Possible Side Effects and Safety Information

Official regulatory documentation, such as the Summary of Product Characteristics (SmPC) and FDA Prescribing Information, classifies the adverse effects of Metfonorm (Metformin Hydrochloride) according to frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most frequently reported effects are classified as Very Common and involve the gastrointestinal system, including diarrhea, nausea, vomiting, abdominal pain, and loss of appetite (anorexia). These gastrointestinal disturbances are officially documented as being most prevalent at the beginning of treatment and generally resolve spontaneously with continued use. Common reactions involve the nervous system, typically manifesting as taste disturbance (dysgeusia).

Serious Safety Considerations

The most serious safety consideration, although classified as Very Rare, is Lactic Acidosis. This potentially life-threatening metabolic complication is a central focus of regulatory constraints. The risk is significantly increased in patients with compromised renal impairment or hepatic impairment, leading to these conditions being official contraindications in many regulatory labels. Furthermore, the official labeling warns against excessive alcohol intake and requires the temporary discontinuation of Metfonorm when undergoing procedures involving iodinated contrast agents.

Duration and Long-Term Use

Adverse effects associated with long-term use include the Very Rare occurrence of decreased Vitamin B12 absorption, which may lead to megaloblastic anemia. The safety profile specifies that patients with pre-existing risk factors may require periodic monitoring for B12 levels during prolonged therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Metfonorm overdose presents a serious risk, primarily due to the potential development of a life-threatening condition called lactic acidosis. This condition involves a dangerous buildup of lactic acid in the blood and requires immediate medical intervention.

Documented Overdose Symptoms

The most common effects of acute overdose include nausea, vomiting, lethargy, and abdominal pain. More severe poisoning can lead to coma, seizures, and cardiovascular collapse. Other symptoms to be aware of include extreme tiredness, weakness, decreased appetite, deep, rapid breathing or shortness of breath, an abnormally fast or slow heartbeat, and feeling cold or dizzy. While not common, symptoms of low blood sugar (hypoglycemia) may also occur.

Emergency Actions Required

Lactic acidosis is particularly associated with serious intoxication and has occurred mostly in patients with impaired kidney function. If an overdose is suspected, contact a healthcare professional or a Poison Control Centre immediately, even if no symptoms are present.

Immediate emergency services (e.g., calling 911) must be contacted if the victim has collapsed, is having a seizure, has trouble breathing, or cannot be awakened. Do not delay seeking emergency medical attention in these circumstances.

Therapeutic Uses of Metfonorm

What Metfonorm Treats: Main Uses and Benefits

Metfonorm is principally used for managing Type 2 Diabetes Mellitus, managing the symptoms related to chronic hyperglycemia. This therapeutic domain is relevant in conditions characterized by periods of heightened symptoms related to systemic imbalance. The medication is applied across domains where additional symptomatic support is needed.

The treatment is commonly used to help with Prediabetes, Type 2 Diabetes Mellitus, and metabolic issues associated with Polycystic Ovary Syndrome (PCOS). It is considered relevant for easing symptoms that create noticeable physiological strain by being applied in addressing the symptoms related to impaired sugar utilization. This usage contributes to improved comfort during periods of heightened symptoms.

Metfonorm is frequently used as a foundational first-line pharmacotherapy or in combination therapy with other agents, when supportive symptom management is appropriate. This provides support that helps ease the overall symptom burden and assists in the effort to maintain stable blood sugar levels.

Quick Fact: Relief for Chronic Hyperglycemia
This medication plays a role in managing symptoms related to impaired sugar utilization, assisting with maintaining functional stability when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

This section outlines the eligibility and non-eligibility for Metfonorm based strictly on official governmental regulatory documentation.

Contraindicated Populations

Metfonorm (metformin) must not be used in patients with certain conditions as specified in official labeling. These include:

  • Severe Renal Impairment: Contraindicated if the estimated glomerular filtration rate ( eGFR) is less than 30 mL/min/1.73 m^2.
  • Metabolic Acidosis: Contraindicated in the presence of acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
  • Hypersensitivity: Contraindicated for individuals with a known serious allergic or hypersensitivity reaction to the drug substance or its components.

Restricted or Monitored Use

Use is restricted or requires special consideration in several populations:

  • Renal Function: The drug is generally not recommended for treatment initiation in patients with an eGFR between 30 mL/min/1.73 m^2 and 45 mL/min/1.73 m^2.
  • Hepatic Impairment: Use is typically avoided in patients with clinical or laboratory evidence of liver disease.
  • Age: The medicine is established for use in adults and pediatric patients ge 10 years of age. For geriatric patients (ge 65 years old), renal function should be assessed more frequently.
  • Procedures: The medicine must be temporarily discontinued for certain procedures, such as radiologic studies involving intravascular iodinated contrast materials or surgical procedures necessitating restricted intake of food and fluids.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metfonorm (Metformin) interactions are defined by regulatory authorities based primarily on its elimination and potential pharmacodynamic effects. The official profile highlights substances that increase Metfonorm's plasma concentration and those that carry a combined risk of severe metabolic outcomes.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Type of Interacting Agent Official Interaction Outcome
Renal Transporter Inhibitors (e.g., Cimetidine, Ranolazine, Dolutegravir) Reduces Metfonorm clearance by inhibiting renal tubular transport (OCT2/MATE), formally increasing Metfonorm's plasma exposure and accumulation risk.
Additive Glucose-Lowering Agents (e.g., Insulin, Sulfonylureas) Creates an additive pharmacodynamic effect that increases the officially documented risk of hypoglycemia.
Carbonic Anhydrase Inhibitors (e.g., Topiramate, Acetazolamide) Officially associated with an increased risk of lactic acidosis.
Hyperglycaemic Agents (e.g., Glucocorticoids, Diuretics) These agents may counter the glucose-lowering effect of Metfonorm.

Restrictions and Timing Requirements

Interactions involving Iodinated Contrast Agents require the temporary cessation of Metfonorm at the time of or prior to the procedure, and withholding for at least 48 hours afterward until renal function is verified as stable. Excessive alcohol intake is formally associated with an increased risk of lactic acidosis. Additionally, regulatory documents note that Metfonorm may formally lower Vitamin B12 serum levels, and caution is required when prescribing to geriatric patients due to documented reductions in total plasma clearance.

Mechanism of Action

Targeting Liver Enzymes to Reduce Glucose Supply

Metfonorm's primary action begins in the liver, where it causes a subtle, non-lethal inhibition of Mitochondrial Complex I in hepatocytes. This alters the cellular energy state, leading to the activation of the enzyme AMPK (Adenosine Monophosphate-Activated Protein Kinase). Activated AMPK suppresses the gene expression and activity of enzymes that drive gluconeogenesis (the synthesis of new glucose). This cascade modifies the early molecular steps that shape systemic physiological outcomes, resulting in a crucial decrease in the net flux of glucose from the liver into the circulation.


Enhancing Peripheral Tissue Sensitivity to Insulin

Beyond the liver, the drug modulates signaling pathways in peripheral tissues, such as skeletal muscle and adipocytes. This mechanism facilitates the cellular response to the body's existing insulin by promoting the movement of glucose transporters (GLUT4) to the cell surface. This activity supports a more regulated state within targeted pathways, allowing for increased uptake and utilization of glucose from the circulation, which modulates systemic glucose levels.

Dosage and Administration Information

Official Administration Guidelines

Metfonorm (Metformin Hydrochloride) is utilized via the oral route in two primary forms: the Immediate-Release (IR) tablet and the Extended-Release (ER) tablet. This difference in formulation dictates the appropriate dosing frequency.

The initiation of therapy involves gradual dose titration. For adults, the IR starting dose is typically 500 mg taken twice daily, with subsequent adjustments occurring weekly or bi-weekly. The IR maximum daily dose is 2550 mg, which is often administered in two or three divided doses. In contrast, the ER formulation is generally taken once daily, beginning at 500 mg to 1000 mg, with a maximum of 2000 mg/ day.

A mandatory rule for administration is to take the medication with meals to optimize tolerability, with ER formulations typically scheduled with the evening meal. The ER tablet must be swallowed whole and must not be crushed, cut, or chewed. If a dose is missed, it should be skipped, and the regular schedule should be resumed without attempting to double the amount.

Official use is critically tied to kidney function. Dosage is constrained by the estimated Glomerular Filtration Rate (eGFR), which must be assessed prior to treatment and monitored annually. Initiation of therapy is not recommended for eGFR 30 to 45 mL/ min/1.73 m^2, and use is officially contraindicated below 30 mL/ min/1.73 m^2. This procedural structure defines the standardized, long-term approach to the medicine's application.

Recent Clinical Evidence

Metfonorm: Recent Clinical Evidence

Research on CA-BS for Knee Osteoarthritis

Research has examined whether CA-BS can affect pain and mobility in patients with severe knee osteoarthritis. Studies have explored the substance's characteristics within the knee joint.

  • Physical Characteristics: Studies have focused on the physical characteristics of CA-BS.
  • Pain and Function: The primary body of evidence consists of clinical trials that have evaluated changes in knee pain and physical function after treatment.

Key Study Findings

A systematic review examining multiple clinical trials included 1,500 adult participants diagnosed with severe knee osteoarthritis. All participants had failed to achieve adequate symptom control using conservative treatments, such as physical therapy and over-the-counter pain medication.

One study compared outcomes for patients who received the treatment to those who received oral NS-AD agents.

Outcomes and Measures

The clinical trials assessed changes in patient symptoms using validated tools:

  • Pain Scoring: Investigators used a visual analog scale (VAS) to track patient-reported pain intensity.
  • Mobility Assessment: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to assess physical function, joint stiffness, and mobility-related difficulties.

The studies explored CA-BS in patients who had not achieved satisfactory relief from other treatments.

Combination Therapy and Long-Term Effects

Research has also investigated patient outcomes when CA-BS was used in combination with a physical therapy regimen.

Further studies have explored the time frame in which patients first reported symptom changes after the injection.

Evidence remains limited regarding the very long-term effects of CA-BS injections (beyond 12 months), and additional research is ongoing to fully characterize the sustained effects.

Frequently Asked Questions (FAQ)

Common questions about Metfonorm (FAQ)


Q: What happens if I accidentally miss a dose of Metfonorm?

A: Official regulatory documents advise that if a dose of Metfonorm is missed, the patient should simply skip that dose entirely. Information advises that patients resume their regular schedule with the next dose. It is important not to take a double dose to compensate for the one that was skipped.

Q: What should I do if I experience severe stomach pain while taking Metfonorm?

A: Severe stomach pain is one potential symptom of a very rare but serious adverse event called Lactic Acidosis. The official label instructs that the medication should be stopped immediately and emergency medical help sought if Lactic Acidosis is suspected.

Q: Will Metfonorm interact with my vitamin supplements?

A: The official product information documents that long-term use of Metfonorm is associated with a risk of decreasing Vitamin B12 serum levels, which may require periodic monitoring. Regulatory documents primarily focus on the B12 interaction and do not offer comprehensive information on all other vitamins or supplements.

Q: Does Metfonorm interact with alcohol?

A: Yes, regulatory warnings state that excessive alcohol consumption is formally associated with an increased risk of Lactic Acidosis. This is a very rare but serious side effect.

Q: What are the lesser-known side effects of Metfonorm?

A: Beyond the very common gastrointestinal issues, documented but lesser-known reactions include a change in sense of taste (dysgeusia), which is common. Very rare effects associated with long-term use include a B12 deficiency that may lead to megaloblastic anemia.

Q: How long can a person safely take Metfonorm?

A: Metfonorm is designed for the long-term management of blood sugar levels. The safety profile notes that prolonged use is associated with a very rare risk of decreased Vitamin B12 absorption, which may require periodic monitoring.

Q: Does Metfonorm cause low blood sugar (hypoglycemia)?

A: Metfonorm alone does not typically cause hypoglycemia (low blood sugar). However, official information documents that the risk of low blood sugar is increased when this medication is used in combination with other glucose-lowering drugs, such as insulin or sulfonylureas.

Q: Can I take Metfonorm with blood pressure medication?

A: Certain classes of blood pressure medication, specifically diuretics (often classified as hyperglycaemic agents), are noted in regulatory documents because they may counter the glucose-lowering effect of Metfonorm. Patients are advised to review the full interaction profile for specific medications.

Q: Does Metfonorm interact with common cold or flu medicines?

A: Some ingredients in common cold and flu medications, such as certain types of decongestants or glucocorticoids (hyperglycaemic agents), may officially counter the glucose-lowering effect of Metfonorm. The full interaction profile for all concurrent medicines should be consulted.

Q: How quickly does Metfonorm start working to lower blood sugar?

A: While some improvement in blood glucose control may start to be noticeable within the first one to two weeks, the medication's full effect takes longer to establish. Regulatory and patient information suggests the full effect of Metfonorm may take up to two to three months.

Q: Does Metfonorm help with weight loss?

A: Official clinical studies do not list weight loss as a primary use for Metfonorm. However, some studies have shown that the medication may be associated with a modest weight loss effect, and it is generally considered to be weight-neutral, meaning it is not expected to cause weight gain.

Q: Does Metfonorm cause fatigue?

A: Fatigue or extreme tiredness is not listed as a common side effect of Metfonorm. However, somnolence or extreme tiredness is officially listed as a potential non-specific symptom associated with Lactic Acidosis, which is a very rare but serious adverse event.

Q: Are there any major diet restrictions while taking Metfonorm?

A: Official administration guidelines state that the medication should be taken with meals to help reduce potential stomach side effects. Additionally, excessive alcohol intake is formally restricted due to the serious risk of Lactic Acidosis.

Q: Can Metfonorm cause metallic taste in the mouth?

A: Yes, a change in sense of taste, formally called dysgeusia, is listed as a common adverse reaction in official documents. This change in taste is often described by patients as a metallic taste.

Q: How does Metfonorm affect cholesterol levels?

A: Official clinical studies indicate that Metfonorm may stabilize or decrease parameters like LDL-cholesterol (often called 'bad' cholesterol) and triglyceride levels. It is not approved solely for cholesterol management.

Q: Can Metfonorm affect fertility?

A: Official product labeling notes that for premenopausal women who do not ovulate (anovulatory women), Metfonorm may cause ovulation. Regulatory information notes this change as a potential factor in unintended pregnancy.

Q: Are there any mood changes associated with Metfonorm use?

A: Mood changes are not commonly listed as a direct side effect. However, post-marketing reports have noted rare occurrences of central nervous system effects such as drowsiness, difficulty with concentrating, or a behavior change similar to intoxication.

Q: Is it normal for my hunger level to change after starting Metfonorm?

A: Yes, official adverse reaction reports classify a decrease in appetite (anorexia) as a very common side effect. This change in hunger level is most frequently reported when first starting treatment.

Q: Can Metfonorm make you dizzy?

A: Dizziness or lightheadedness are not listed as common side effects. However, official safety documents list dizziness as a potential symptom associated with two different serious events: Lactic Acidosis and hypoglycemia (low blood sugar).

Q: Why might a doctor switch me from immediate-release to extended-release Metfonorm?

A: Official labeling notes that the extended-release (ER) formulation is often chosen to improve tolerability. The ER form is sometimes used for patients who experience frequent gastrointestinal sensitivity (stomach upset) with the immediate-release form.

Q: Is it normal to have digestive issues when starting Metfonorm?

A: Yes, digestive issues such as diarrhea, nausea, vomiting, and abdominal pain are classified as Very Common adverse reactions. Official documentation confirms these effects are most frequent at the beginning of treatment.

Q: What is the expected duration of the stomach side effects after starting Metfonorm?

A: Official regulatory documents indicate that the most common gastrointestinal side effects are most prevalent when treatment begins. They are typically expected to resolve spontaneously with continued use of the medication.

Q: Why is my doctor suggesting I take Metfonorm even though my A1C is only slightly high?

A: Metfonorm is generally a recommended initial therapy for blood sugar control. Its use sometimes extends to managing early glucose dysregulation, though the primary regulatory indications focus on established Type 2 diabetes.

Q: Does Metfonorm affect how other medications are absorbed?

A: Metfonorm is officially documented to interfere with the absorption of Vitamin B12. Regulatory information primarily focuses on how other medications, such as renal transporter inhibitors, can affect Metfonorm's own plasma concentration and elimination, rather than the other way around.

How should Metfonorm be stored and disposed of?

Metfonorm (metformin hydrochloride) tablets must be stored according to official regulatory requirements to ensure product quality.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Store in a tight, light-resistant container; keep tightly closed to protect from moisture and light.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Metfonorm must be disposed of according to local regulations for pharmaceutical waste. The official labeling states that the medicine should not be thrown away via wastewater or household waste. Patients are advised to utilize available medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metfonorm found in:

A-Z Index: